Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2018 - 201922020 - 20231

Settings

Subject: search.filters.subject.epithelial ovarian cancer

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Oncologic and Obstetric Outcomes of Early-Stage Epithelial Ovarian Cancer Patients Who Underwent Fertility-Sparing Surgery: A Retrospective Study
    (2023) Ayhan, Ali; Tunc, Mehmet; Atasoy Karakas, Latife; Tekelioglu, Tugba; Haberal Reyhan, Asuman Nihan; Onalan, Gogsen; Kuscu, Esra; 0000-0002-8646-0619; 0000-0001-7369-5470; 36825554; AAA-6962-2022; AAI-8793-2021
    ObjectiveThis study aimed to assess the long-term oncologic and obstetric outcomes of women with epithelial ovarian cancer who underwent fertility-sparing surgery. MethodsA total of 68 patients observed between March 2007 and July 2021 were included in this retrospective study. Unilateral salpingo-oophorectomy and uterine preservation with staging surgery were the main procedures for fertility-sparing surgery. Disease-free, overall survival, and obstetric outcomes were measured as primary outcomes. ResultsThe median age of the patients was 30.5 years. The median follow-up time was 60.5 months. Disease recurrence occurred in 15 (22.1%) of the patients. Five-year disease-free survival and overall survival (OS) percentages were 75.6% and 83.3%, respectively, for all stages. The FIGO (International Federation of Gynecology & Obstetrics) stage was the only significant factor that affected OS (P = 0.001). Twenty-three patients tried to conceive, and 15 (65.2%) patients became pregnant. Twelve (80%) pregnancies reached term and resulted in 15 live births. Chemotherapy administration and surgical intervention (cystectomy or unilateral salpingo-oophorectomy) showed no difference in pregnancy results (P = 0.806 and P = 0.066, respectively). ConclusionFertility preservation is safe for invasive epithelial ovarian cancer at early stages for women in the reproductive era. Disease recurrence and OS results are similar to standard treatment at early stages with decent obstetric outcomes.
  • No Thumbnail Available
    Item
    Effect of Increased Number of Neoadjuvant Chemotherapy Cycles on Tumor Resectability and Pathologic Response in Advanced Stage Epithelial Ovarian Cancer
    (2018) Akilli, Huseyin; Rahatli, Samed; Tohma, Yusuf Aytac; Karakas, Latife Atasoy; Altundag, Ozden; Ayhan, Ali; 0000-0002-5240-8441; 0000-0003-3163-7429; 0000-0001-9418-4733; 0000-0003-0197-6622; AAX-3230-2020; AAJ-3047-2021; AAE-6482-2021; AEY-5060-2022; W-9219-2019; AAJ-5802-2021
    Purpose: To identify the significance of the number of neoadjuvant chemotherapy (NACT) cycles on pathologic response and to define relationship between multiple cycles of NACT and the timing of interval debulking surgery (IDS) in epithelial ovarian cancer (EOC) patients. Methods: This retrospective case-control study was carried out at the Baskent University in Ankara between 2007 and 2017. We reviewed 62 patients with advanced stage (IIIC-IV) EOC who received NACT in other institutes and operated in our clinic. On the basis of the number of NACT cycles, patients were divided into 2 groups: group 1 received 3 cycles and group 2 received 4 to 6 cycles.The influence of the number of NACT cycles on complete pathologic response, lymph node involvement, overall survival (OS), progression free survival (PFS), platinum resistance and residual tumor were evaluated. Results: The median OS was 44.4 +/- 4.8 months and 48.8 +/- 4.49 months for group 1 and group 2 respectively (p=0.122). PFS was 19.3 +/- 3.75 months in group 1 and 24.3 +/- 4.67 months in group 2 (p=0.84). Tumor morphology according to lymph node involvement, no visible tumor and complete pathologic response were similar for both groups (p=0.49, p=0.79 and p=0.6 respectively). Pathological absence of residual disease were 13.6% vs 7.5% for group 1 and group 2 respectively (p=0.6) and complete pathologic response rate was 6/62 (9.67%). Platinum resistance developed in 4(18.2%) patients and 18(45%) patients in group 1 and 2 respectively (p=0.031). Complete resection rates were similar for both groups (p=0.9). After multivariate survival analyses, complete resection remained significant (p=0.000, odds ratio/ OR 2.28 [1.41-3.701]), and was independent of age, platinum resistance and number of NACT cycles. Complete resection rates were almost equal in each groups, (68.2% [15/22] and 67.5% [27/40] for group 1 and group 2 respectively (p=0.9)). Conclusions: Our data suggests that giving more than 3 cycles of NACT is unnecessary because increased number of cycles did not change the resectability and complete pathologic response, while it increased platinum resistance. Moreover OS and PFS remained similar.
  • No Thumbnail Available
    Item
    Comparison of survival outcomes in optimally and maximally cytoreduced stage IIIC ovarian high-grade serous carcinoma: Women with only peritoneal tumor burden versus women with both peritoneal and lymphogenous dissemination
    (2019) Selcuk, Ilker; Meydanli, Mehmet M.; Yalcin, Ibrahim; Gungorduk, Kemal; Akgol, Sedat; Celik, Husnu; Ayhan, Ali; 31373110
    Aim The aim of this study was to analyze the survival outcomes of stage IIIC ovarian high-grade serous carcinoma (HGSC) patients with both peritoneal and lymphatic dissemination (IP+/RP+) who had undergone maximal or optimal cytoreduction followed by intravenous carboplatin/paclitaxel chemotherapy compared to those women with stage IIIC ovarian HGSC with only peritoneal involvement (IP+/RP-) who were treated similarly. Methods We performed a retrospective, multicenter study with the participation of five gynecological cancer centers. First, the stage IIIC ovarian HGSC patients were classified into optimally or maximally debulked cohorts. Then, in each cohort, the patients were divided into two groups; the IP+/RP- group included those women with transcoelomic spreading outside the pelvis with no nodal disease, and the IP+/RP+ group included those patients with transcoelomic dissemination outside the pelvis in addition to a positive nodal status. The survival outcomes were compared between the two groups in each cohort. Results A total of 405 ovarian HGSC patients were analyzed. In the optimally debulked cohort (n = 257), the progression-free survival (PFS) and overall survival (OS) medians for the IP+/RP- group (n = 69) were 24 and 57 months, respectively, compared to 21 and 58 months, respectively, for the IP+/RP+ group (n = 188) (P = 0.78 and P = 0.40, respectively). In the maximally debulked cohort (n = 148), the PFS and OS medians for the IP+/RP- group (n = 55) were 35 and 63 months, respectively, compared to 25 and 51 months, respectively, for the IP+/RP+ group (n = 93) (P = 0.49 and P = 0.31, respectively). Conclusion Our findings indicated no survival differences between the IP+/RP- and the IP+/RP+ groups.